Objective: Interventions that combat obesity and its associated metabolic perturbations may decrease incidence and improve outcomes of endometrial cancer (EC). Potential options for weight loss include pharmacotherapeutic interventions such as tirzepatide, a dual-acting glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. Given this, we explored the anti-obesity and anti-tumorigenic effects of tirzepatide in our pre-clinical mouse model of endometrioid EC.

Methods: Starting at 4 weeks of age, Lkb1p53 mice were fed a low-fat diet vs a high-fat diet to generate a lean or obese phenotype. Nine weeks after induction of EC, obese and lean mice were randomized to receive tirzepatide for 4 weeks. Body and tumor weights, tumor transcriptomic and metabolomic profiles, and serum metabolic markers and chemokines were assessed.

Results: Both obese and lean mice began to lose body weight after 2 weeks of tirzepatide treatment, ultimately achieving a significant weight loss of 20.1 % in obese mice and 16.8 % in lean mice. Tirzepatide improved obesity-induced serum adiponectin, leptin, GIP, and C-reactive protein levels. Furthermore, tirzepatide relative to vehicle, effectively reduced tumor growth in obese and lean mice, inhibited the ErbB signaling and glycolysis/gluconeogenesis in tumors of obese mice, and increased O-linked glycosylation biosynthesis and phospholipase D signaling in tumors of lean mice.

Conclusion: Tirzepatide decreased both mouse weight and tumor growth via effects on metabolic and immune pathways in the EC tumors that differed between obese and lean mice. This novel weight loss treatment deserves further evaluation as an innovative strategy in the management of EC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2024.10.004DOI Listing

Publication Analysis

Top Keywords

lean mice
20
obese lean
16
weight loss
12
tirzepatide
8
endometrial cancer
8
mice
8
obese mice
8
tumor growth
8
lean
7
obese
7

Similar Publications

Fighting Fire with Fire: Impact of Sugary Diets on Metabolically Deranged Mice.

Nutrients

December 2024

Department of Neuroscience & Behavior, Barnard College, Columbia University, New York, NY 10027, USA.

There is controversy about the health risks of sugary diets. A recent study reported that chronic consumption of 11% sugar solutions improved glycemic control in lean mice. Based on this finding, we hypothesized that chronic consumption of the same 11% sugar solutions would also improve glycemic control in metabolically deranged mice.

View Article and Find Full Text PDF

Omega-3 (ω-3) polyunsaturated fatty acids in fish oil have been shown to prevent diet-induced obesity in lean mice and to promote heat production in adipose tissue. However, the effects of fish oil on obese animals remain unclear. This study investigated the effects of fish oil in obese mice.

View Article and Find Full Text PDF

Deficiency of hepatokine orosomucoid1 aggravates NAFLD progression in mice.

Biochim Biophys Acta Mol Basis Dis

January 2025

Department of Clinical Pharmacy, School of Pharmacy, Naval Medical University/Second Military Medical University, Shanghai 200433, China. Electronic address:

Orosomucoid (ORM) is an important hepatokine that regulates metabolism. Previous report showed that isoform ORM2 but not ORM1 could downregulate lipogenic genes and ameliorate hepatic steatosis in obese mice, thereby categorizing ORM2 as a promising candidate for therapeutic intervention in nonalcoholic fatty liver disease (NAFLD). However, our previous studies found that mice lacking ORM1 gradually developed an obese phenotype with severe hepatic steatosis at the age of 24 weeks.

View Article and Find Full Text PDF

The direct and indirect inhibition of proinflammatory adipose tissue macrophages by acarbose in diet-induced obesity.

Cell Rep Med

December 2024

Medical Research Center, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Immunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; General Surgery Department, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; Beijing Laboratory of Oral Health, Capital Medical University School of Basic Medicine, Beijing 100069, China; Beijing Key Laboratory of Tolerance Induction and Organ Protection in Transplantation, Beijing Friendship Hospital, Beijing 100050, China. Electronic address:

Article Synopsis
  • Acarbose plays a significant role in reducing inflammation related to obesity and insulin resistance by influencing adipose tissue macrophages (ATMs).
  • Acarbose promotes the growth of beneficial gut bacteria that produce propionic acid, which helps inhibit the proinflammatory M1-like ATMs.
  • The study shows that acarbose directly targets and inhibits these inflammatory macrophages, suggesting its potential for therapeutic use in managing obesity and insulin resistance.
View Article and Find Full Text PDF

Gut protects against fat deposition by enhancing secondary bile acid biosynthesis.

Imeta

December 2024

Key Laboratory of Hunan Province for the Products Quality Regulation of Livestock and Poultry College of Animal Science and Technology, Hunan Agricultural University Changsha China.

Gut microbiome is crucial for lipid metabolism in humans and animals. However, how specific gut microbiota and their associated metabolites impact fat deposition remains unclear. In this study, we demonstrated that the colonic microbiome of lean and obese pigs differentially contributes to fat deposition, as evidenced by colonic microbiota transplantation experiments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!